{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:26:36Z","timestamp":1792592796109,"version":"4.5.0"},"reference-count":89,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nitric oxide (NO) signaling represents one of the major regulatory pathways for cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998, this signaling cascade was stepwise clarified. We now have a good understanding of NO production and NO downstream targets such as the soluble guanylyl cyclases (sGCs) which catalyze cGMP production. Based on the important role of NO-signaling in the cardiovascular system, intense research and development efforts are currently ongoing to fully exploit the therapeutic potential of cGMP increase. Recently, NO-independent stimulators of sGC (sGC stimulators) were discovered and characterized. This new compound class has a unique mode of action, directly binding to sGC and triggering cGMP production. The first sGC stimulator made available to patients is riociguat, which was approved in 2013 for the treatment of different forms of pulmonary hypertension (PH). Besides riociguat, other sGC stimulators are in clinical development, with vericiguat in phase 3 clinical development for the treatment of chronic heart failure (HF). Based on the broad impact of NO\/cGMP signaling, sGC stimulators could have an even broader therapeutic potential beyond PH and HF. Within this review, the NO\/sGC\/cGMP\/PKG\/PDE-signaling cascade and the major pharmacological intervention sites are described. In addition, the discovery and mode of action of sGC stimulators and the clinical development in PH and HF is covered. Finally, the preclinical and clinical evidence and treatment approaches for sGC stimulators beyond these indications and the cardiovascular disease space, like in fibrotic diseases as in systemic sclerosis (SSc), are reviewed.<\/jats:p>","DOI":"10.1515\/hsz-2018-0155","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T16:35:52Z","timestamp":1522859752000},"page":"679-690","source":"Crossref","is-referenced-by-count":87,"title":["From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators"],"prefix":"10.1515","volume":"399","author":[{"given":"Peter","family":"Sandner","sequence":"first","affiliation":[{"name":"Bayer AG, Drug-Discovery, Pharma Research Center Wuppertal , Aprather Weg 18a , D-42069 Wuppertal , Germany"},{"name":"Hannover Medical School, Department of Pharmacology , Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"2023040406490854353_j_hsz-2018-0155_ref_001_w2aab3b7c90b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Abdelaziz, N., Colombo, F., Mercier, I., and Calderone, A. (2001). Nitric oxide attenuates the expression of transforming growth factor-\u03b2(3) mRNA in rat cardiac fibroblasts via destabilization. Hypertension 38, 261\u2013266.","DOI":"10.1161\/01.HYP.38.2.261"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_002_w2aab3b7c90b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Armstrong, P.W., Roessig, L., Patel, M.J., Anstrom, K.J., Butler, J., Voors, A.A., Lam, C.S.P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018). A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail. 6, 96\u2013104.","DOI":"10.1016\/j.jchf.2017.08.013"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_003_w2aab3b7c90b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Beavo, J.A. and Brunton, L.L. (2002). Cyclic nucleotide research \u2013 still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3, 710\u2013718.","DOI":"10.1038\/nrm911"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_004_w2aab3b7c90b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Bender, A.T. and Beavo, J.A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488\u2013520.","DOI":"10.1124\/pr.58.3.5"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_005_w2aab3b7c90b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Bernabeu, R., Schmitz, P., Faillace, M.P., Izquierdo, I., and Medina, J.H. (1996). Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 7, 585\u2013588.","DOI":"10.1097\/00001756-199601310-00050"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_006_w2aab3b7c90b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Beuve, A. (2017). Thiol-based redox modulation of soluble guanylyl cyclase, the nitric oxide receptor. Antioxid. Redox. Signal. 26, 137\u2013149.","DOI":"10.1089\/ars.2015.6591"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_007_w2aab3b7c90b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Beyer, C., Schett, G., Distler, O., and Distler, J.H. (2010). Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 62, 2831\u20132844.","DOI":"10.1002\/art.27647"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_008_w2aab3b7c90b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Beyer, C., Reich, N., Schindler, S.C., Akhmetshina, A., Dees, C., Tomcik, M., Hirth-Dietrich, C., von Degenfeld, G., Sandner, P., Distler, O., et al. (2012). Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann. Rheum. Dis. 71, 1019\u20131026.","DOI":"10.1136\/annrheumdis-2011-200862"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_009_w2aab3b7c90b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Beyer, C., Zenzmaier, C., Palumbo-Zerr, K., Mancuso, R., Distler, A., Dees, C., Zerr, P., Huang, J., Maier, C., Pachowsky, M.L., et al. (2015). Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling. Ann. Rheum. Dis. 74, 1408\u20131416.","DOI":"10.1136\/annrheumdis-2013-204508"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_010_w2aab3b7c90b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Bice, J.S., Keim, Y., Stasch, J.P., and Baxter, G.F. (2014). NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc. Res. 101, 220\u2013228.","DOI":"10.1093\/cvr\/cvt257"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_011_w2aab3b7c90b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Breitenstein, S., Roessig, L., Sandner, P., and Lewis, K.S. (2017). Novel sGC stimulators and sGC activators for the treatment of heart failure. Handb. Exp. Pharmacol. 243, 225\u2013247.","DOI":"10.1007\/164_2016_100"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_012_w2aab3b7c90b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Dees, C., Beyer, C., Distler, A., Soare, A., Zhang, Y., Palumbo-Zerr, K., Distler, O., Schett, G., Sandner, P., and Distler, J.H. (2015). Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann. Rheum. Dis. 74, 1621\u20131625.","DOI":"10.1136\/annrheumdis-2014-206809"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_013_w2aab3b7c90b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Derbyshire, E.R. and Marletta, M.A. (2009). Biochemistry of soluble guanylate cyclase. Handb. Exp. Pharmacol. 191, 17\u201331.","DOI":"10.1007\/978-3-540-68964-5_2"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_014_w2aab3b7c90b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Derbyshire, E.R. and Marletta, M.A. (2012). Structure and regulation of soluble guanylate cyclase. Annu. Rev. Biochem. 81, 533\u2013559.","DOI":"10.1146\/annurev-biochem-050410-100030"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_015_w2aab3b7c90b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Dumitrascu, R., Weissmann, N., Ghofrani, H.A., Dony, E., Beuerlein, K., Schmidt, H., Stasch, J.P., Gnoth, M.J., Seeger, W., Grimminger, F., et al. (2006). Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113, 286\u2013295.","DOI":"10.1161\/CIRCULATIONAHA.105.581405"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_016_w2aab3b7c90b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Dunkern, T.R., Feurstein, D., Rossi, G.A., Sabatini, F., and Hatzelmann, A. (2007). Inhibition of TGF-\u03b2 induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 572, 12\u201322.","DOI":"10.1016\/j.ejphar.2007.06.036"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_017_w2aab3b7c90b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Emdin, C.A., Khera, A.V., Klarin, D., Natarajan, P., Zekavat, S.M., Nomura, A., Haas, M., Aragam, K., Ardissino, D., Wilson, J.G., et al. (2018). Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling. Circulation. 16, 137, 222\u2013232.","DOI":"10.1161\/CIRCULATIONAHA.117.028021"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_018_w2aab3b7c90b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Evgenov, O.V., Ichinose, F., Evgenov, N.V., Gnoth, M.J., Falkowski, G.E., Chang, Y., Bloch, K.D., and Zapol, W.M. (2004). Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110, 2253\u20132259.","DOI":"10.1161\/01.CIR.0000144469.01521.8A"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_019_w2aab3b7c90b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Evgenov, O.V., Zou, L., Zhang, M., Mino-Kenudson, M., Mark, E.J., Buys, E.S., Raher, M.J., Li, Y., Feng, Y., Jones, R.C., et al. (2011). Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis. BMC Pharmacol. 11, O9. doi:10.1186\/1471-2210-11-s1-o9.","DOI":"10.1186\/1471-2210-11-S1-O9"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_020_w2aab3b7c90b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Fesenko, E.E., Kolesnikov, S.S., and Lyubarsky, A.L. (1985). Induction by cyclic GMP of cationic conductance in plasma membrane of retinal rod outer segment. Nature 313, 310\u2013313.","DOI":"10.1038\/313310a0"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_021_w2aab3b7c90b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Filippatos, G., Maggioni, A.P., Lam, C.S.P., Pieske-Kraigher, E., Butler, J., Spertus, J., Ponikowski, P., Shah, S.J., Solomon, S.D., Scalise, A.V., et al. (2017). Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur. J. Heart Fail. 19, 782\u2013791.","DOI":"10.1002\/ejhf.800"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_022_w2aab3b7c90b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Flores-Costa, R., Alcaraz-Quiles, J., Titos, E., L\u00f3pez-Vicario, C., Casulleras, M., Duran-G\u00fcell, M., Rius, B., Diaz, A., Hall, K., Shea, C., et al. (2017). The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br. J. Pharmacol. 175, 953\u2013967.","DOI":"10.1111\/bph.14137"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_023_w2aab3b7c90b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Follmann, M., Ackerstaff, J., Redlich, G., Wunder, F., Lang, D., Kern, A., Fey, P., Griebenow, N., Kroh, W., Becker-Pelster, E.M., et al. (2017). Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J. Med. Chem. 60, 5146\u20135161.","DOI":"10.1021\/acs.jmedchem.7b00449"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_024_w2aab3b7c90b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Freitas, C.F., Morganti, R.P., Annichino-Bizzacchi, J.M., De Nucci, G., and Antunes, E. (2007). Effect of BAY 41\u20132272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. Clin. Exp. Pharmacol. Physiol. 34, 10\u201314.","DOI":"10.1111\/j.1440-1681.2007.04524.x"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_025_w2aab3b7c90b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Frey, R., Muck, W., Unger, S., Artmeier-Brandt, U., Weimann, G., and Wensing, G. (2008). Single-dose pharmacokinetics, tolerability and safety of the soluble guanylate cyclase stimulator BAY 63\u20132521; an ascending-dose study in healthy male volunteers. J. Clin. Pharmacol. 48, 926\u2013934.","DOI":"10.1177\/0091270008319793"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_026_w2aab3b7c90b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Frey, R., Becker, C., Saleh, S., Unger, S., van der Mey, D., and M\u00fcck, W. (2017). Clinical pharmacokinetic and pharmacodynamic profile of Riociguat. Clin. Pharmacokinet. doi: 10.1007\/s40262-017-0604-7. [Epub ahead of print].","DOI":"10.1007\/s40262-017-0604-7"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_027_w2aab3b7c90b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Friebe, A., Sandner, P., and Schmidtko, A. (2017). Meeting report of the 8th International Conference on cGMP \u201ccGMP: generators, effectors and therapeutic implications\u201d at Bamberg, Germany from June 23rd to 25th 2017. Naunyn-Schmiedeberg\u2019s Arch. Pharmacol. 390, 1177\u20131188.","DOI":"10.1007\/s00210-017-1429-5"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_028_w2aab3b7c90b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Furchgott, R.F. and Zawadzki, J.V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373\u2013376.","DOI":"10.1038\/288373a0"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_029_w2aab3b7c90b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Geschka, S., Kretschmer, A., Sharkovska, Y., Evgenov, O.V., Lawrenz, B., Hucke, A., Hocher, B., and Stasch, J.P. (2011). Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 6, e21853.","DOI":"10.1371\/journal.pone.0021853"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_030_w2aab3b7c90b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Gheorghiade, M., Greene, S.J., Butler, J., Filippatos, G., Lam, C.S., Maggioni, A.P., Ponikowski, P., Shah, S.J., Solomon, S.D., Kraigher-Krainer, E., et al. (2015). Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in Patients with Worsening Chronic Heart Failure and Reduced Ejection Fraction: the SOCRATES-REDUCED Randomized Trial. J. Am. Med. Assoc. 314, 2251\u20132262.","DOI":"10.1001\/jama.2015.15734"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_031_w2aab3b7c90b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Ghofrani, H.A., Hoeper, M.M., Halank, M., Meyer, F.J., Staehler, G., Behr, J., Ewert, R., Weimann, G., and Grimminger, F. (2010a). Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur. Respir. J. 36, 792\u2013799.","DOI":"10.1183\/09031936.00182909"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_032_w2aab3b7c90b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Ghofrani, H.A., Hoeper, M.M., Halank, M., Meyer, F.J., Staehler, G., Behr, J., Ewert, R., Binnen, T., Weimann, G., and Grimminger, F. (2010b). Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: first long-term extension data from a phase II study. Am. J. Respir. Crit. Care Med. 181, A6770.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A6770"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_033_w2aab3b7c90b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Ghofrani, H.A., D\u2019Armini, A.M., Grimminger, F., Hoeper, M.M., Jansa, P., Kim, N.H., Mayer, E., Simonneau, G., Wilkins, M.R., Fritsch, A., et al. (2013a). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369, 319\u2013329.","DOI":"10.1056\/NEJMoa1209657"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_034_w2aab3b7c90b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Ghofrani, H.A., Gali\u00e8, N., Grimminger, F., Grunig, E., Humbert, M., Jing, Z.C., Keogh, A.M., Langleben, D., Kilama, M.O., Fritsch, A., et al. (2013b). Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330\u2013340.","DOI":"10.1056\/NEJMoa1209655"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_035_w2aab3b7c90b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Ghofrani, H.A., Grimminger, F., Grunig, E., Huang, Y., Jansa, P., Jing, Z.C., Kilpatrick, D., Langleben, D., Rosenkranz, S., Menezes, F., et al. (2016). Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 4, 361\u2013371.","DOI":"10.1016\/S2213-2600(16)30019-4"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_036_w2aab3b7c90b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Grimminger, F., Weimann, G., Frey, R., Voswinckel, R., Thamm, M., B\u00f6lkow, D., Weissmann, N., Muck, W., Unger, S., Wensing, G., et al. (2009). First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 33, 785\u2013792.","DOI":"10.1183\/09031936.00039808"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_037_w2aab3b7c90b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Hanrahan, J., Profy, A.T., Lavins, B.J., Ruff, D., Poirier, G., Wakefield, J., Wilson, P., Hall, M., and Currie, M.G. (2016). First-in-human single-ascending-dose study of IW-1973, a new soluble guanylate cyclase stimulator. JACC 67, 1284.","DOI":"10.1016\/S0735-1097(16)31285-2"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_038_w2aab3b7c90b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Hewitson, T.D., Martic, M., Darby, I.A., Kelynack, K.J., Bisucci, T., Tait, M.G., and Becker, G.J. (2004). Intracellular cyclic nucleotide analogues inhibit in vitro mitogenesis and activation of fibroblasts derived from obstructed rat kidneys. Nephron. Exp. Nephrol. 96, e59\u201366.","DOI":"10.1159\/000076405"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_039_w2aab3b7c90b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Hoeper, M.M., Simonneau, G., Corris, P.A., Ghofrani, H.A., Klinger, J.R., Langleben, D., Naeije, R., Jansa, P., Rosenkranz, S., Scelsi, L., et al. (2017). RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur. Respir. J. 50, 1602425.","DOI":"10.1183\/13993003.02425-2016"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_040_w2aab3b7c90b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 84, 9265\u20139269.","DOI":"10.1073\/pnas.84.24.9265"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_041_w2aab3b7c90b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Ignarro, L.J., Byrns, R.E., Buga, G.M., Wood, K.S., and Chaudhuri, G. (1988). Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J. Pharmacol. Exp. Ther. 244, 181\u2013189.","DOI":"10.1016\/S0022-3565(25)24231-8"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_042_w2aab3b7c90b1b6b1ab2b2c42Aa","unstructured":"Ironwood Pharmaceuticals. (2017). Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects (Cambridge, MA: Press Release IW-Pharmaceuticals), Dec 4."},{"key":"2023040406490854353_j_hsz-2018-0155_ref_043_w2aab3b7c90b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Irvine, J.C., Ganthavee, V., Love, J.E., Alexander, A.E., Horowitz, J.D., Stasch, J.P., Kemp-Harper, B.K., and Ritchie, R.H. (2012). The soluble guanylyl cyclase activator Bay 58-2667 selectively limits cardiomyocyte hypertrophy. PLoS One 7, e44481.","DOI":"10.1371\/journal.pone.0044481"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_044_w2aab3b7c90b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Kalk, P., Godes, M., Relle, K., Rothkegel, C., Hucke, A., Stasch, J.P., and Hocher, B. (2006). NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy. Br. J. Pharmacol. 148, 853\u2013859.","DOI":"10.1038\/sj.bjp.0706792"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_045_w2aab3b7c90b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Knorr, A., Hirth-Dietrich, C., Alonso-Alija, C., H\u00e4rter, M., Hahn, M., Keim, Y., Wunder, F., and Stasch, J.P. (2008). Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58, 71\u201380.","DOI":"10.1055\/s-0031-1296471"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_046_w2aab3b7c90b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs, \u00c1., Alogna, A., Post, H., and Hamdani, N. (2016). Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Neth. Heart J. 24, 268\u2013274.","DOI":"10.1007\/s12471-016-0814-x"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_047_w2aab3b7c90b1b6b1ab2b2c47Aa","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger, M., K\u00f6tter, S., Gr\u00fctzner, A., Lang, P., Andresen, C., Redfield, M.M., Butt, E., dos Remedios, C.G., and Linke, W.A. (2009). Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res. 104, 87\u201394.","DOI":"10.1161\/CIRCRESAHA.108.184408"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_048_w2aab3b7c90b1b6b1ab2b2c48Aa","doi-asserted-by":"crossref","unstructured":"Lang, M., Kojonazarov, B., Tian, X., Kalymbetov, A., Weissmann, N., Grimminger, F., Kretschmer, A., Stasch, J.P., Seeger, W., Ghofrani, H.A., et al. (2012). The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 7, e43433.","DOI":"10.1371\/journal.pone.0043433"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_049_w2aab3b7c90b1b6b1ab2b2c49Aa","doi-asserted-by":"crossref","unstructured":"Leineweber, K., Moosmang, S., and Paulson, D. (2017). Genetics of no deficiency. Am. J. Cardiol. 120 (Suppl.), S80\u2013S88.","DOI":"10.1016\/j.amjcard.2017.06.013"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_050_w2aab3b7c90b1b6b1ab2b2c50Aa","doi-asserted-by":"crossref","unstructured":"Leslie, M. (2016). Celebrity molecules promised to transform our health, but haven\u2019t always lived up to their billing. Science 353, 1198\u20131201.","DOI":"10.1126\/science.353.6305.1198"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_051_w2aab3b7c90b1b6b1ab2b2c51Aa","doi-asserted-by":"crossref","unstructured":"Lewis, K.S., Butler, J., Bauersachs, J., and Sandner, P. (2017). The three-decade long journey in heart failure drug development. Handb. Exp. Pharmacol. 243, 1\u201314.","DOI":"10.1007\/164_2016_101"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_052_w2aab3b7c90b1b6b1ab2b2c52Aa","doi-asserted-by":"crossref","unstructured":"Masuyama, H., Tsuruda, T., Kato, J., Imamura, T., Asada, Y., Stasch, J.P., Kitamura, K., and Eto, T. (2006). Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48, 972\u2013978.","DOI":"10.1161\/01.HYP.0000241087.12492.47"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_053_w2aab3b7c90b1b6b1ab2b2c53Aa","doi-asserted-by":"crossref","unstructured":"Masuyama, H., Tsuruda, T., Sekita, Y., Hatakeyama, K., Imamura, T., Kato, J., Asada, Y., Stasch, J.P., and Kitamura, K. (2009). Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens. Res. 32, 597\u2013603.","DOI":"10.1038\/hr.2009.64"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_054_w2aab3b7c90b1b6b1ab2b2c54Aa","doi-asserted-by":"crossref","unstructured":"Matei, A.E., Beyer, C., Gy\u00f6rfi, A.H., Soare, A., Chen, C.W., Dees, C., Bergmann, C., Ramming, A., Friebe, A., Hofmann, F., et al. (2018). Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann. Rheum. Dis. 77, 459. doi:10.1136. [EPub ahead of print].","DOI":"10.1136\/annrheumdis-2017-212489"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_055_w2aab3b7c90b1b6b1ab2b2c55Aa","doi-asserted-by":"crossref","unstructured":"Mathar, I., Kretschmer, A., Hartmann, E., Kolkhof, P., and Sandner, P. (2017). Combination of soluble guanylate cyclase stimulation and mineralocorticoid receptor antagonism as new treatment option for heart failure with preserved ejection fraction (HFpEF): results from a preclinical study with vericiguat and finerenone. Circulation 136, A17778.","DOI":"10.1161\/circ.136.suppl_1.21000"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_056_w2aab3b7c90b1b6b1ab2b2c56Aa","doi-asserted-by":"crossref","unstructured":"Methner, C., Buonincontri, G., Hu, C.H., Vujic, A., Kretschmer, A., Sawiak, S., Carpenter, A., Stasch, J.P., and Krieg, T. (2013). Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI\/PET imaging. PLoS One 8, e83910.","DOI":"10.1371\/journal.pone.0083910"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_057_w2aab3b7c90b1b6b1ab2b2c57Aa","doi-asserted-by":"crossref","unstructured":"M\u00fclsch, A., Bauersachs, J., Sch\u00e4fer, A., Stasch, J.P., Kast, R., and Busse, R. (1997). Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120, 681\u2013689.","DOI":"10.1038\/sj.bjp.0700982"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_058_w2aab3b7c90b1b6b1ab2b2c58Aa","unstructured":"Murad, F. (1998). Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Prog. Horm. Res. 53, 43\u201359."},{"key":"2023040406490854353_j_hsz-2018-0155_ref_059_w2aab3b7c90b1b6b1ab2b2c59Aa","doi-asserted-by":"crossref","unstructured":"Murrell, W. (1879). Nitro-glycerin as a remedy for angina pectoris. Lancet 113, 80\u201381.","DOI":"10.1016\/S0140-6736(02)46032-1"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_060_w2aab3b7c90b1b6b1ab2b2c60Aa","doi-asserted-by":"crossref","unstructured":"Nakai, T., Perl, N.R., Barden, T.C., Carvalho, A., Fretzen, A., Germano, P., Im G.Y., Jin, H., Kim, C., Lee, T.W., et al. (2016). Discovery of IWP-051, a novel orally bioavailable sGC stimulator with once-daily dosing potential in humans. ACS Med. Chem. Lett. 7, 465\u2013469.","DOI":"10.1021\/acsmedchemlett.5b00479"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_061_w2aab3b7c90b1b6b1ab2b2c61Aa","unstructured":"Nowatzky, J., Wintermeyer, P., von Degenfeld, G., Hirth-Dietrich, C., and Sandner, P. (2011). Antifibrotic effect of the SGC-stimulator bay 41-2272 in the bile duct ligation liver fibrosis model in rats. Hepatology 54 (4 Suppl.), 755A 838."},{"key":"2023040406490854353_j_hsz-2018-0155_ref_062_w2aab3b7c90b1b6b1ab2b2c62Aa","doi-asserted-by":"crossref","unstructured":"Pacher, P., Beckman, J.S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315\u2013424.","DOI":"10.1152\/physrev.00029.2006"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_063_w2aab3b7c90b1b6b1ab2b2c63Aa","doi-asserted-by":"crossref","unstructured":"Paul, T., Salazar-Degracia, A., Peinado, V.I., Tura-Ceide, O., Blanco, I., Barreiro, E., and Barber\u00e0, J.A. (2018). Soluble guanylate cyclase stimulation reduces oxidative stress in experimental chronic obstructive pulmonary disease. PLoS One 5, e0190628.","DOI":"10.1371\/journal.pone.0190628"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_064_w2aab3b7c90b1b6b1ab2b2c64Aa","doi-asserted-by":"crossref","unstructured":"Pieske, B., Butler, J., Filippatos, G., Lam, C., Maggioni, A.P., Ponikowski, P., Shah, S., Solomon, S., Kraigher-Krainer, E., Samano, E.T., et al. (2014). Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur. J. Heart Fail. 16, 1026\u20131038.","DOI":"10.1002\/ejhf.135"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_065_w2aab3b7c90b1b6b1ab2b2c65Aa","doi-asserted-by":"crossref","unstructured":"Pieske, B., Maggioni, A.P., Lam, C.S.P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S.J., Solomon, S.D., Scalise, A.V., et al. (2017). Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heart failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J. 38, 1119\u20131127.","DOI":"10.1093\/eurheartj\/ehw593"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_066_w2aab3b7c90b1b6b1ab2b2c66Aa","doi-asserted-by":"crossref","unstructured":"Prickaerts, J., van Staveren, W.C., Sik, A., Markerink-van Ittersum, M., Niew\u00f6hner, U., van der Staay, F.J., Blokland, A., and de Vente, J. (2002). Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113, 351\u2013361.","DOI":"10.1016\/S0306-4522(02)00199-9"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_067_w2aab3b7c90b1b6b1ab2b2c67Aa","doi-asserted-by":"crossref","unstructured":"Potoka, K.P., Wood, K.C., Baust, J.J., Bueno, M., Hahn, S.A., Vanderpool, R.R., Bachman, T., Mallampalli, G.M., Osei-Hwedieh, D.O., Schrott, V., et al. (2017). NO-independent sGC activation improves vascular function and cardiac remodeling in sickle cell disease. Am J Respir Cell Mol Biol. doi: 10.1165\/rcmb.2017-0292OC. [Epub ahead of print].","DOI":"10.1165\/rcmb.2017-0292OC"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_068_w2aab3b7c90b1b6b1ab2b2c68Aa","doi-asserted-by":"crossref","unstructured":"Rai, N., Veeroju, S., Schymura, Y., Janssen, W., Wietelmann, A., Kojonazarov, B., Weissmann, N., Stasch, J.P., Ghofrani, H.A., Seeger, W., et al. (2018). Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding. BioMed. Res. Int. 2018. Article ID 3293584 (in press).","DOI":"10.1155\/2018\/3293584"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_069_w2aab3b7c90b1b6b1ab2b2c69Aa","doi-asserted-by":"crossref","unstructured":"Rutten, K., Vente, J.D., Sik, A., Ittersum, M.M., Prickaerts, J., and Blokland, A. (2005). The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav. Brain Res. 164, 11\u201316.","DOI":"10.1016\/j.bbr.2005.04.021"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_070_w2aab3b7c90b1b6b1ab2b2c70Aa","doi-asserted-by":"crossref","unstructured":"Rutten, K., Basile, J.L., Prickaerts, J., Blokland, A., and Vivian, J.A. (2007). Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl). 196, 643\u2013648.","DOI":"10.1007\/s00213-007-0999-1"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_071_w2aab3b7c90b1b6b1ab2b2c71Aa","doi-asserted-by":"crossref","unstructured":"Sandner, P. and Stasch, J.P. (2017). Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir. Med. 122 (Suppl. 1), S1\u2013S9.","DOI":"10.1016\/j.rmed.2016.08.022"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_072_w2aab3b7c90b1b6b1ab2b2c72Aa","doi-asserted-by":"crossref","unstructured":"Sandner, P., Neuser, D., and Bischoff, E. (2009). Erectile dysfunction and lower urinary tract. Handb. Exp. Pharmacol. 191, 507\u2013531.","DOI":"10.1007\/978-3-540-68964-5_22"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_073_w2aab3b7c90b1b6b1ab2b2c73Aa","doi-asserted-by":"crossref","unstructured":"Sandner, P., Berger, P., and Zenzmaier, C. (2017). The Potential of sGC modulators for the treatment of age-related fibrosis: a mini-review. Gerontology 63, 216\u2013227.","DOI":"10.1159\/000450946"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_074_w2aab3b7c90b1b6b1ab2b2c74Aa","doi-asserted-by":"crossref","unstructured":"Schermuly, R., Stasch, J.P., Pullamsetti, S.S., Middendorff, R., Mueller, D., Schlueter, K.D., Dingendorf, A., Hackemack, S., Kolosionek, E., Kaulen, C., et al. (2008). Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 32, 881\u2013891.","DOI":"10.1183\/09031936.00114407"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_075_w2aab3b7c90b1b6b1ab2b2c75Aa","doi-asserted-by":"crossref","unstructured":"Schlossmann, J. and Desch, M. (2009). cGK substrates. Handb. Exp. Pharmacol. 191, 163\u2013193.","DOI":"10.1007\/978-3-540-68964-5_9"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_076_w2aab3b7c90b1b6b1ab2b2c76Aa","doi-asserted-by":"crossref","unstructured":"Schlossmann, J. and Desch, M. (2011). IRAG and novel PKG targeting in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 301, H672\u2013H682.","DOI":"10.1152\/ajpheart.00198.2011"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_077_w2aab3b7c90b1b6b1ab2b2c77Aa","doi-asserted-by":"crossref","unstructured":"Schmidt, H.H., Schmidt, P.M., and Stasch, J.P. (2009). NO- and haem-independent soluble guanylate cyclase activators. Handb. Exp. Pharmacol. 191, 309\u2013339.","DOI":"10.1007\/978-3-540-68964-5_14"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_078_w2aab3b7c90b1b6b1ab2b2c78Aa","doi-asserted-by":"crossref","unstructured":"Sharkovska, Y., Kalk, P., Lawrenz, B., Godes, M., Hoffmann, L.S., Wellkisch, K., Geschka, S., Relle, K., Hocher, B., and Stasch, J.P. (2010). Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J. Hypertens. 28, 1666\u20131675.","DOI":"10.1097\/HJH.0b013e32833b558c"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_079_w2aab3b7c90b1b6b1ab2b2c79Aa","doi-asserted-by":"crossref","unstructured":"Simonneau, G., D\u2019Armini, A.M., Ghofrani, H.A., Grimminger, F., Jansa, P., Kim, N.H., Mayer, E., Pulido, T., Wang, C., Colorado, P., et al. (2016). Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 4, 372\u2013380.","DOI":"10.1016\/S2213-2600(16)30022-4"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_080_w2aab3b7c90b1b6b1ab2b2c80Aa","doi-asserted-by":"crossref","unstructured":"Stasch, J.P. and Hobbs, A.J. (2009). NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 191, 277\u2013308.","DOI":"10.1007\/978-3-540-68964-5_13"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_081_w2aab3b7c90b1b6b1ab2b2c81Aa","doi-asserted-by":"crossref","unstructured":"Stasch, J.P. and Evgenov, O.V. (2013). Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 218, 279\u2013313.","DOI":"10.1007\/978-3-642-38664-0_12"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_082_w2aab3b7c90b1b6b1ab2b2c82Aa","doi-asserted-by":"crossref","unstructured":"Stasch, J.P., Schmidt, P., Alonso-Alija, C., Apeler, H., Dembowsky, K., Haerter, M., Heil, M., Minuth, T., Perzborn, E., Pleiss, U., et al. (2002). NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 136, 773\u2013783.","DOI":"10.1038\/sj.bjp.0704778"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_083_w2aab3b7c90b1b6b1ab2b2c83Aa","doi-asserted-by":"crossref","unstructured":"Stasch, J.P., Pacher, P., and Evgenov, O.V. (2009). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263\u20132273.","DOI":"10.1161\/CIRCULATIONAHA.110.981738"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_084_w2aab3b7c90b1b6b1ab2b2c84Aa","doi-asserted-by":"crossref","unstructured":"Stasch, J.P., Schlossmann, J., and Hocher, B. (2015). Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr. Opin. Pharmacol. 21, 95\u2013104.","DOI":"10.1016\/j.coph.2014.12.014"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_085_w2aab3b7c90b1b6b1ab2b2c85Aa","doi-asserted-by":"crossref","unstructured":"Tsai, E.J. and Kass, D.A. (2009). Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol. Ther. 122, 216\u2013238.","DOI":"10.1016\/j.pharmthera.2009.02.009"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_086_w2aab3b7c90b1b6b1ab2b2c86Aa","doi-asserted-by":"crossref","unstructured":"Umar, S. and van der Laarse, A. (2010). Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol. Cell Biochem. 333, 191\u2013201.","DOI":"10.1007\/s11010-009-0219-x"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_087_w2aab3b7c90b1b6b1ab2b2c87Aa","doi-asserted-by":"crossref","unstructured":"Weidenbach, A., Stasch, J.P., Ghofrani, H.A., Weissmann, N., Grimminger, F., Seeger, W., and Schermuly, R.T. (2005). Inhaled NO and the guanylate cyclase stimulator BAY 41\u20132272 in oleic acid induced acute lung injury in rabbits. BMC Pharmacol. 5, P61.","DOI":"10.1186\/1471-2210-5-S1-P61"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_088_w2aab3b7c90b1b6b1ab2b2c88Aa","doi-asserted-by":"crossref","unstructured":"Weissmann, N., Lobo, B., Pichl, A., Parajuli, N., Seimetz, M., Puig-Pey, R., Ferrer, E., Peinado, V.I., Dom\u00ednguez-Fandos, D., Fysikopoulos, A., et al. (2014). Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am. J. Respir. Crit. Care Med. 189, 1359\u20131373.","DOI":"10.1164\/rccm.201311-2037OC"},{"key":"2023040406490854353_j_hsz-2018-0155_ref_089_w2aab3b7c90b1b6b1ab2b2c89Aa","doi-asserted-by":"crossref","unstructured":"Zenzmaier, C., Kern, J., Heitz, M., Plas, E., Zwerschke, W., Mattesich, M., Sandner, P., and Berger, P. (2015). Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells. Exp. Cell Res. 338, 162\u2013169.","DOI":"10.1016\/j.yexcr.2015.08.014"}],"container-title":["Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/bchm.2018.399.issue-7\/hsz-2018-0155\/hsz-2018-0155.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0155\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:38:22Z","timestamp":1751546302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0155\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":89,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,6,12]]},"published-print":{"date-parts":[[2018,6,27]]}},"alternative-id":["10.1515\/hsz-2018-0155"],"URL":"https:\/\/doi.org\/10.1515\/hsz-2018-0155","relation":{},"ISSN":["1437-4315","1431-6730"],"issn-type":[{"value":"1437-4315","type":"electronic"},{"value":"1431-6730","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,30]]}}}